Valuation: PharmaEngine, Inc.

Market Cap 803.16Cr 25Cr 22Cr 20Cr 19Cr 35Cr 2.35TCr 35Cr 245.92Cr 98Cr 1.23TCr 93Cr 91Cr 3.91TCr P/E 2024
7.42x
P/E 2025 26.2x
Enterprise Value 335.69Cr 10Cr 9.28Cr 8.56Cr 7.76Cr 15Cr 983.78Cr 15Cr 102.79Cr 41Cr 514.83Cr 39Cr 38Cr 1.63TCr EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.29%
Yield 2024
6.64%
Yield 2025 2.84%
1 day-0.53%
1 week-1.58%
Current month+0.54%
1 month+0.72%
3 months-15.17%
6 months+2.76%
Current year-20.60%
1 week 55.4
Extreme 55.4
57.3
1 month 55
Extreme 55
58
Current year 53
Extreme 53
74
1 year 53
Extreme 53
74.4
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
197
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 17/05/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 19/01/2018
Director/Board Member - 15/05/2018
Director/Board Member - 13/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-1.58%-17.55%-48.00% 25Cr
-3.10%-3.43%+36.29%+67.69% 6.53TCr
+0.33%+7.26%+11.51%+77.95% 5.46TCr
+0.16%+3.69%+8.39%+101.27% 5.36TCr
-0.75%+2.13%+23.14%+47.25% 4.5TCr
-1.30%-1.11%+17.77%+120.71% 4.22TCr
+1.26%+2.23%+241.81%+835.31% 3.94TCr
-0.74%-4.84%+14.53%+44.45% 3.27TCr
-2.70%-7.34%+23.17%+0.36% 2.4TCr
+1.11%+17.90%+56.87%+47.78% 2.65TCr
Average -0.63%+1.62%+41.59%+129.48% 3.84TCr
Weighted average by Cap. -0.72%+1.72%+45.12%+148.52%

Financials

2024 2025
Net sales 252.33Cr 7.78Cr 6.98Cr 6.44Cr 5.84Cr 11Cr 739.49Cr 11Cr 77Cr 31Cr 386.99Cr 29Cr 29Cr 1.23TCr 91Cr 2.81Cr 2.52Cr 2.33Cr 2.11Cr 3.94Cr 267.1Cr 4Cr 28Cr 11Cr 139.78Cr 11Cr 10Cr 443.63Cr
Net income 175.1Cr 5.4Cr 4.84Cr 4.47Cr 4.05Cr 7.57Cr 513.16Cr 7.68Cr 54Cr 21Cr 268.55Cr 20Cr 20Cr 852.3Cr 39Cr 1.19Cr 1.07Cr 98.9L 89.66L 1.68Cr 113.6Cr 1.7Cr 12Cr 4.71Cr 59Cr 4.48Cr 4.39Cr 188.68Cr
Net Debt -385.37Cr -12Cr -11Cr -9.83Cr -8.91Cr -17Cr -1.13TCr -17Cr -118Cr -47Cr -591.02Cr -45Cr -44Cr -1.88TCr -467.47Cr -14Cr -13Cr -12Cr -11Cr -20Cr -1.37TCr -21Cr -143.14Cr -57Cr -716.94Cr -54Cr -53Cr -2.28TCr
Projected Income Statement - Annual - PharmaEngine, Inc.
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
27/26/27 NT$55.90 -0.53% 1,89,906
22/26/22 NT$56.20 0.00% 1,60,751
21/26/21 NT$56.20 -0.71% 1,76,738
20/26/20 NT$56.60 -0.35% 1,14,279
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - PharmaEngine, Inc.

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PharmaEngine, Inc.
  1. Stock Market
  2. Stocks
  3. 4162 Stock